Overview of distinct 8-oxoguanine profiles of messenger RNA in normal and senescent cancer cells

正常细胞和衰老癌细胞中信使RNA的8-氧鸟嘌呤谱特征概述

阅读:1

Abstract

BACKGROUND: Cellular senescence plays a key role in the development of cancer, but the underlying mechanisms are unknown. Recently, several recent studies have shown that RNA methylation is closely related to cancer cell aging. 8-Oxoguanine (o(8)G) is an important and widely distributed methylation modification whose role in cancer cell senescence is far from elucidated. METHODS: In this study, senescent cancer cell models (CaCO(2) cells) were constructed by knocking down the ADAR1 gene. RNA immunoprecipitation sequencing was used to identify the o(8)G peaks on messenger RNA (mRNA) of normal CaCO(2) cells and senescent CaCO(2) cells, and the distribution characteristics of mRNA o(8)G modification were identified. Further bioinformatics analysis of the sequencing data was performed to preliminarily elucidate the potential function of the o(8)G-modified mRNA. RESULTS: There were significant differences in mRNA o(8)G modification distribution between normal and senescent CaCO(2) cells. It is suggested that o(8)G modification may play a key role in inducing cancer cells or promoting cancer cell senescence. Gene ontology (GO) enrichment analysis showed that the mRNAs modified by o(8)G were enriched in Cellular component organization or biogenesis, Focal adhesion, and RNA binding. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that the genes modified by o(8)G are concentrated in Focal adhesion signaling pathway, Small cell lung cancer signaling pathway and Proteoglycans in cancer signaling pathway. CONCLUSION: This study preliminarily revealed the different distribution patterns of o(8)G modification between normal CaCO(2) cells and senescent CaCO(2) cells. Our study established the link between o(8)G modification and cancer cell senescence, which provides a new insight into the mechanism of cancer cell senescence and a potential therapeutic target for subsequent cancer treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。